Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Safety and Efficacy of the CiTop™ ExPander™ Guidewire for Crossing Chronic Total Occlusions in Coronary Arteries

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Informed consent obtained prior to any trial activities.~2. Patients, male or female between 21 and 80 years of age, with no significant co-morbidities (see exclusion criteria).~3. Patient has an angiographic documented Chronic Total Occlusion showing distal TIMI flow 0 to 1.~Exclusion Criteria:~1. Patient unable to give informed consent.~2. Current participation in another study with any investigational drug or device.~3. Factors making follow-up and/or repeat angiography difficult or unlikely.~4. Contra-indication to emergency artery by pass surgery.~5. Lack of surgical backup.~6. Contra-indication to treatment with Aspirin, or Clopidogrel and/or Heparin.~7. Lesion \> 40mm in length (both calcified lesion and adjacent thrombus).~8. Treated vessel referenced diameter less than 2.5 mm.~9. Visualization of the distal lumen less than the Rentrop Classification Grade 2 collateralization.~10. Non-visible entry point of target lesion.~11. Totally occluded bypass graft as target vessel.~12. Acute MI less than 1 week before procedure.~13. Patient has significant LV dysfunction, 35% LVEF or less.~14. Patient with cancer or other sever chronic disease with life expectance of 2 years.~15. Patient has chronic renal failure with serum creatinine ≥2.~16. Hemoglobin ≤11.~17. Patient is known or suspected not to tolerate the contrast agent.~18. Morbid Obesity (BMI \> 40).~19. Drug abuse or alcoholism.~20. Patients under custodial care.~21. Pregnant women or women with childbearing potential with a positive pregnancy test at the time of procedure.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).